Evidence map›Paper›PMID 31155639›Full record

ArticleCarcinogenesis2019

Impacts of the MHC class I-like XNC10 and innate-like T cells on tumor tolerance and rejection in the amphibian Xenopus.

Maureen Banach, Eva-Stina Edholm, Xavier Gonzalez, Abdellatif Benraiss, Jacques Robert

Open access · bronzeAbstract read
In one paragraph

Article in Carcinogenesis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Maureen BanachDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, USA.
Eva-Stina EdholmThe Norwegian College of Fishery Science, UiT The Arctic University of Norway, Tromsø, Norway.
Xavier GonzalezDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, USA.
Abdellatif BenraissDepartment of Neurology, University of Rochester Medical Center, Rochester, NY, USA.
Jacques RobertDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, USA.
University of Rochester Medical Center · USUiT The Arctic University of Norway · NO

Funding

A Xenopus Laevis Research Resource for ImmunologyR24AI059830 · NIAID · UNIVERSITY OF ROCHESTER · PI JACQUES Robert · 2004 to 2026
$7.7M
The role of The Xenopus Nonclassical MHC class I molecule XNC10 in Tumor ImmunityF31CA192664 · NCI · UNIVERSITY OF ROCHESTER · PI BANACH, MAUREEN LUDMILA · 2015 to 2018
$153k
NCI NIH HHS F31 CA192664NIAID NIH HHS R24 AI059830
6 · The paper itself

Abstract

The conditions that lead to antitumor or protumor functions of natural killer T (NKT) cells against mammalian tumors are only partially understood. Therefore, insights into the evolutionary conservation of NKT and their analogs-innate-like T (iT) cells-may reveal factors that contribute to tumor eradication. As such, we investigated the amphibian Xenopus laevis iT cells and interacting MHC class I-like (XNC or mhc1b.L) genes against ff-2 thymic lymphoid tumors. Upon ff-2 intraperitoneal transplantation into syngeneic tadpoles, two iT cell subsets iVα6 and iVα22, characterized by an invariant T-cell receptor α chain rearrangement (Vα6-Jα1.43 and Vα22-Jα1.32 respectively), were recruited to the peritoneum, concomitant with a decreased level of these transcripts in the spleen and thymus. To address the hypothesize that different iT cell subsets have distinct, possibly opposing, roles upon ff-2 tumor challenge, we determined whether ff-2 tumor growth could be manipulated by impairing Vα6 iT cells or by deleting their restricting element, the XNC gene, XNC10 (mhc1b10.1.L), on ff-2 tumors. Accordingly, the in vivo depletion of Vα6 iT cells using XNC10-tetramers enhanced tumor growth, indicating Vα6 iT cell-mediated antitumor activities. However, XNC10-deficient transgenic tadpoles that also lack Vα6 iT cells were resistant to ff-2 tumors, uncovering a potential new function of XNC10 besides Vα6 iT cell development. Furthermore, the CRISPR/Cas9-mediated knockout of XNC10 in ff-2 tumors broke the immune tolerance. Together, our findings demonstrate the relevance of XNC10/iT cell axis in controlling Xenopus tumor tolerance or rejection.

Indexed as

AnimalsAnimals, Genetically ModifiedCell Line, TumorDisease Models, AnimalGene Knockout TechniquesHistocompatibility Antigens Class IHumansLarvaNatural Killer T-CellsReceptors, Antigen, T-Cell, alpha-betaThymus NeoplasmsT-Lymphocyte SubsetsTumor EscapeXenopus laevisXenopus ProteinsHistocompatibility Antigens Class Imhc1b.L protein, XenopusReceptors, Antigen, T-Cell, alpha-betaXenopus Proteins

Identifiers

PMID31155639
PMCPMC6642367
OpenAlexW2948285508

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.